Rezolute, Inc. (RZLT) 10-Year Financial Performance & Capital Metrics

RZLT • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesObesity & Metabolic Disorders

AboutRezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.Show more

Revenue $0
EBITDA -$80M -13.5%
Net Income -$74M -8.7%
EPS (Diluted) -0.98 +26.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -52.56% +8.9%
ROIC -97.85% -44.0%
Debt/Equity 0.01 -45.9%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 1.2x book value

✗Weaknesses

✗Weak momentum: RS Rating 3 (bottom 3%)
✗Shares diluted 47.7% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-11.36%

EPS CAGR

10Y-

5Y-

3Y-

TTM27.34%

ROCE

10Y Avg-4273.62%

5Y Avg-58.85%

3Y Avg-51.91%

Latest-55.73%

Peer Comparison

Obesity & Metabolic Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MNKDMannKind Corporation	1.73B	5.64	58.02	43.5%	9.32%		1.89%
CORTCorcept Therapeutics Incorporated	3.82B	36.35	29.55	39.94%	14.19%	16.65%	5.12%	0.01
GUTSFractyl Health, Inc. Common Stock	308.28M	2.01	-1.24	-22.5%	-40732.33%	-241.68%		2.20
LXRXLexicon Pharmaceuticals, Inc.	436.08M	1.20	-1.90	24.81%	-96.77%	-57.07%		0.74
RZLTRezolute, Inc.	229.96M	2.48	-2.53			-52.45%		0.01
MISTMilestone Pharmaceuticals Inc.	164.38M	1.93	-2.88	-100%		-282.97%		4.17
ALTAltimmune, Inc.	418.41M	4.01	-2.99	-95.31%	-4195.75%	-45.21%		0.01
BIOABioAge Labs, Inc.	741.84M	20.69	-3.12		-12.81%	-27.32%		0.03

Profit & Loss

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	8.27M	12.57M	1.07M	48K	18K	13K	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-8.27M	-12.57M	-1.07M	-48K	-18K	-13K	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-0.41%	-0.52%	0.92%	0.95%	0.63%	0.28%	1%	-	-	-
Operating Expenses+	14.95M	20.32M	26.38M	25.9M	20.5M	22.88M	41.84M	55.99M	70.42M	79.89M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	5.5M	8.23M	9.1M	6.82M	6.07M	7.91M	9.36M	12.18M	14.68M	18.37M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	9.45M	12.09M	17.28M	19.08M	14.45M	14.99M	32.49M	43.81M	55.74M	61.53M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	5.33M	37.14K	136.13K	0	0	0	0	0	0	0
Operating Income+	-14.95M	-20.32M	-28.73M	-25.94M	-20.52M	-22.89M	-41.84M	-55.99M	-70.42M	-79.89M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.4%	-0.36%	-0.41%	0.1%	0.21%	-0.12%	-0.83%	-0.34%	-0.26%	-0.13%
EBITDA+	-14.2M	-19.21M	-27.67M	-25.9M	-20.5M	-22.88M	-41.83M	-55.96M	-70.39M	-79.86M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.34%	-0.35%	-0.44%	0.06%	0.21%	-0.12%	-0.83%	-0.34%	-0.26%	-0.13%
D&A (Non-Cash Add-back)	751.25K	1.11M	1.07M	48K	18K	13K	13K	30K	36K	31K
EBIT	-14.93M	-20.28M	-29.17M	-25.49M	-20.33M	-20.53M	-39.25M	-55.99M	-70.42M	-79.89M
Net Interest Income+	-4.07K	0	-688.19K	-4.9M	188K	-312K	-1.73M	4.21M	4.87M	5.48M
Interest Income	965	0	1K	61K	188K	63K	80K	4.21M	4.87M	5.48M
Interest Expense	5.04K	1.59K	689.19K	4.96M	0	375K	1.81M	0	0	0
Other Income/Expense	15.75K	46.92K	-1.13M	-4.5M	188K	1.99M	783K	4.2M	1.96M	5.48M
Pretax Income+	-14.94M	-20.28M	-29.86M	-30.45M	-20.33M	-20.9M	-41.06M	-51.79M	-68.46M	-74.41M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	-19.82K	-11.37K	0	-29K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-14.94M	-20.28M	-29.86M	-30.42M	-20.33M	-20.9M	-41.06M	-51.79M	-68.46M	-74.41M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-0.31%	-0.36%	-0.47%	-0.02%	0.33%	-0.03%	-0.96%	-0.26%	-0.32%	-0.09%
Net Income (Continuing)	-14.94M	-20.28M	-29.86M	-30.45M	-20.33M	-20.9M	-41.06M	-51.79M	-68.46M	-74.41M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-30.14	-24.55	-26.83	-17.11	-3.54	-2.72	-2.32	-1.01	-1.33	-0.98
EPS Growth %	-0.11%	0.19%	-0.09%	0.36%	0.79%	0.23%	0.15%	0.56%	-0.32%	0.26%
EPS (Basic)	-30.14	-24.55	-26.83	-17.11	-3.54	-2.72	-2.26	-1.01	-1.33	-0.98
Diluted Shares Outstanding	495.46K	825.93K	1.11M	1.78M	5.75M	7.67M	19.49M	51.19M	51.47M	76M
Basic Shares Outstanding	495.46K	825.93K	1.11M	1.78M	5.75M	7.67M	18.2M	51.19M	51.47M	76M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Total Current Assets+	4.49M	4.93M	2.01M	12.14M	10.52M	41.99M	152.1M	104.91M	128.65M	171.15M
Cash & Short-Term Investments	4.06M	4.49M	1.65M	11.57M	9.96M	41.05M	150.41M	101.9M	126.87M	167.86M
Cash Only	4.06M	4.49M	1.65M	11.57M	9.96M	41.05M	150.41M	16.04M	70.4M	94.11M
Short-Term Investments	0	0	0	0	0	0	0	85.86M	56.48M	73.75M
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	430.09K	442.01K	361.92K	571K	0	0	0	0	1.78M	3.29M
Total Non-Current Assets+	6.41M	5.7M	495.1K	108K	447K	616K	316K	18.81M	4.08M	4.34M
Property, Plant & Equipment	5.98M	5.33M	368.37K	44K	416K	425K	168K	2.19M	1.98M	1.42M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	51.61K	44.32K	37.03K	29K	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	16.47M	263K	0
Other Non-Current Assets	375K	330.63K	89.69K	35K	31K	191K	148K	148K	1.84M	2.92M
Total Assets+	10.9M	10.63M	2.5M	12.25M	10.96M	42.61M	152.42M	123.72M	132.74M	175.49M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.03%	-0.03%	-0.76%	3.9%	-0.11%	2.89%	2.58%	-0.19%	0.07%	0.32%
Total Current Liabilities+	1.73M	1.77M	6.25M	8.38M	3.23M	1.97M	2.46M	5.2M	9.61M	11.91M
Accounts Payable	1.5M	926.04K	1.71M	563K	893K	1.03M	1.13M	3.27M	4.9M	5.81M
Days Payables Outstanding	66.26	26.89	584.34	4.28K	18.11K	29.06K	-	-	-	-
Short-Term Debt	83.13K	10K	3.44M	10K	0	0	0	0	0	0
Deferred Revenue (Current)	15.08K	108.06K	1000K	0	0	0	0	0	0	0
Other Current Liabilities	108.52K	131.08K	335.88K	6.53M	120K	77K	0	883K	1.81M	2.27M
Current Ratio	2.60x	2.78x	0.32x	1.45x	3.26x	21.34x	61.78x	20.18x	13.39x	14.37x
Quick Ratio	2.60x	2.78x	0.32x	1.45x	3.26x	21.34x	61.78x	20.18x	13.39x	14.37x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	400.04K	329.62K	215.62K	2.12M	374K	14.54M	487K	2.35M	2.13M	1.45M
Long-Term Debt	0	0	0	0	0	13.97M	0	0	0	0
Capital Lease Obligations	0	0	0	0	165K	187K	80K	1.94M	1.66M	983K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	329.62K	215.62K	2.12M	209K	387K	407K	412K	468K	468K
Total Liabilities	2.13M	2.1M	6.46M	10.5M	3.6M	16.51M	2.95M	7.55M	11.73M	13.36M
Total Debt+	83.13K	10K	3.43M	10K	410K	14.42M	188K	2.48M	2.23M	1.61M
Net Debt	-3.98M	-4.48M	1.79M	-11.56M	-9.54M	-26.63M	-150.22M	-13.56M	-68.17M	-92.49M
Debt / Equity	0.01x	0.00x	-	0.01x	0.06x	0.55x	0.00x	0.02x	0.02x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-2967.11x	-12742.35x	-41.69x	-5.23x	-	-61.05x	-23.16x	-	-	-
Total Equity+	8.77M	8.53M	-3.96M	1.75M	7.37M	26.1M	149.47M	116.17M	121M	162.13M
Equity Growth %	-0.03%	-0.03%	-1.46%	1.44%	3.2%	2.54%	4.73%	-0.22%	0.04%	0.34%
Book Value per Share	17.71	10.33	-3.56	0.99	1.28	3.40	7.67	2.27	2.35	2.13
Total Shareholders' Equity	8.77M	8.53M	-3.96M	1.75M	7.37M	26.1M	149.47M	116.17M	121M	162.13M
Common Stock	35.11K	49.23K	62.17K	210K	6K	8K	34K	37K	53K	87K
Retained Earnings	-44.04M	-64.32M	-94.18M	-126.9M	-147.24M	-168.14M	-209.2M	-260.99M	-329.44M	-403.86M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-879.25K	-1.99M	-517.79K	0	0	0	0	-351K	-79K	-7K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Cash from Operations+	-10.49M	-13.31M	-14.11M	-15.3M	-24.17M	-20.44M	-39.62M	-44.48M	-57.37M	-69.08M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.48%	-0.27%	-0.06%	-0.08%	-0.58%	0.15%	-0.94%	-0.12%	-0.29%	-0.2%
Net Income	-14.94M	-20.28M	-29.86M	-30.45M	-20.33M	-20.9M	-41.06M	-51.79M	-68.46M	-74.41M
Depreciation & Amortization	751.25K	1.11M	1.07M	49K	18K	13K	13K	30K	36K	31K
Stock-Based Compensation	3.76M	6.01M	5.1M	2.64M	3.32M	3.96M	3.69M	7.27M	7.36M	7.12M
Deferred Taxes	0	0	2.93M	-17K	102K	-1.78M	0	-1.36M	0	0
Other Non-Cash Items	53.15K	1.2K	5.63M	4.12M	222K	384K	-1.61M	352K	595K	-1.86M
Working Capital Changes	-119.2K	-155.36K	1.03M	8.36M	-7.49M	-2.12M	-642K	1.02M	3.1M	47K
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	26.37K	112.35K	824.45K	-548K	330K	142K	-11K	2.14M	1.08M	1.42M
Cash from Investing+	-1.45M	-195.38K	1.73M	231K	0	0	0	-101.46M	48.7M	-14.54M
Capital Expenditures	-2.09M	-407.93K	-5.82K	-47K	0	0	0	-153K	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	637.67K	212.55K	1.74M	278	0	0	0	-101.46M	0	0
Cash from Financing+	10.73M	13.93M	9.54M	25M	22.55M	51.53M	148.98M	11.57M	63.03M	107.33M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-890.36K	-683.19K	-299.27K	0	-1.5M	-4.47M	31.39M	-759K	14.01M	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-12.58M	-13.72M	-14.12M	-15.35M	-24.17M	-20.44M	-39.62M	-44.63M	-57.37M	-69.08M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-0.23%	-0.09%	-0.03%	-0.09%	-0.57%	0.15%	-0.94%	-0.13%	-0.29%	-0.2%
FCF per Share	-25.39	-16.61	-12.68	-8.64	-4.20	-2.66	-2.03	-0.87	-1.11	-0.91
FCF Conversion (FCF/Net Income)	0.70x	0.66x	0.47x	0.50x	1.19x	0.98x	0.96x	0.86x	0.84x	0.93x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-167.56%	-234.41%	-1307.66%	-1736.13%	-446.05%	-124.92%	-46.77%	-38.99%	-57.73%	-52.56%
Return on Invested Capital (ROIC)	-256.42%	-344.65%	-2293.34%	-	-	-	-	-82.45%	-67.95%	-97.85%
Debt / Equity	0.01x	0.00x	-	0.01x	0.06x	0.55x	0.00x	0.02x	0.02x	0.01x
Interest Coverage	-2967.11x	-12742.35x	-41.69x	-5.23x	-	-61.05x	-23.16x	-	-	-
FCF Conversion	0.70x	0.66x	0.47x	0.50x	1.19x	0.98x	0.96x	0.86x	0.84x	0.93x

Frequently Asked Questions

Growth & Financials

Rezolute, Inc. (RZLT) grew revenue by 0.0% over the past year. Growth has been modest.

Rezolute, Inc. (RZLT) reported a net loss of $77.2M for fiscal year 2025.

Dividend & Returns

Rezolute, Inc. (RZLT) has a return on equity (ROE) of -52.6%. Negative ROE indicates the company is unprofitable.

Rezolute, Inc. (RZLT) had negative free cash flow of $70.5M in fiscal year 2025, likely due to heavy capital investments.

US Stock Screener

...

Rezolute, Inc. (RZLT) 10-Year Financial Performance & Capital Metrics

RZLT • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesObesity & Metabolic Disorders

Revenue $0
EBITDA -$80M -13.5%
Net Income -$74M -8.7%
EPS (Diluted) -0.98 +26.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -52.56% +8.9%
ROIC -97.85% -44.0%
Debt/Equity 0.01 -45.9%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 1.2x book value

✗Weaknesses

✗Weak momentum: RS Rating 3 (bottom 3%)
✗Shares diluted 47.7% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-11.36%

EPS CAGR

10Y-

5Y-

3Y-

TTM27.34%

ROCE

10Y Avg-4273.62%

5Y Avg-58.85%

3Y Avg-51.91%

Latest-55.73%

Peer Comparison

Obesity & Metabolic Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MNKDMannKind Corporation	1.73B	5.64	58.02	43.5%	9.32%		1.89%
CORTCorcept Therapeutics Incorporated	3.82B	36.35	29.55	39.94%	14.19%	16.65%	5.12%	0.01
GUTSFractyl Health, Inc. Common Stock	308.28M	2.01	-1.24	-22.5%	-40732.33%	-241.68%		2.20
LXRXLexicon Pharmaceuticals, Inc.	436.08M	1.20	-1.90	24.81%	-96.77%	-57.07%		0.74
RZLTRezolute, Inc.	229.96M	2.48	-2.53			-52.45%		0.01
MISTMilestone Pharmaceuticals Inc.	164.38M	1.93	-2.88	-100%		-282.97%		4.17
ALTAltimmune, Inc.	418.41M	4.01	-2.99	-95.31%	-4195.75%	-45.21%		0.01
BIOABioAge Labs, Inc.	741.84M	20.69	-3.12		-12.81%	-27.32%		0.03

Profit & Loss

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	8.27M	12.57M	1.07M	48K	18K	13K	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-8.27M	-12.57M	-1.07M	-48K	-18K	-13K	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-0.41%	-0.52%	0.92%	0.95%	0.63%	0.28%	1%	-	-	-
Operating Expenses+	14.95M	20.32M	26.38M	25.9M	20.5M	22.88M	41.84M	55.99M	70.42M	79.89M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	5.5M	8.23M	9.1M	6.82M	6.07M	7.91M	9.36M	12.18M	14.68M	18.37M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	9.45M	12.09M	17.28M	19.08M	14.45M	14.99M	32.49M	43.81M	55.74M	61.53M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	5.33M	37.14K	136.13K	0	0	0	0	0	0	0
Operating Income+	-14.95M	-20.32M	-28.73M	-25.94M	-20.52M	-22.89M	-41.84M	-55.99M	-70.42M	-79.89M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.4%	-0.36%	-0.41%	0.1%	0.21%	-0.12%	-0.83%	-0.34%	-0.26%	-0.13%
EBITDA+	-14.2M	-19.21M	-27.67M	-25.9M	-20.5M	-22.88M	-41.83M	-55.96M	-70.39M	-79.86M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.34%	-0.35%	-0.44%	0.06%	0.21%	-0.12%	-0.83%	-0.34%	-0.26%	-0.13%
D&A (Non-Cash Add-back)	751.25K	1.11M	1.07M	48K	18K	13K	13K	30K	36K	31K
EBIT	-14.93M	-20.28M	-29.17M	-25.49M	-20.33M	-20.53M	-39.25M	-55.99M	-70.42M	-79.89M
Net Interest Income+	-4.07K	0	-688.19K	-4.9M	188K	-312K	-1.73M	4.21M	4.87M	5.48M
Interest Income	965	0	1K	61K	188K	63K	80K	4.21M	4.87M	5.48M
Interest Expense	5.04K	1.59K	689.19K	4.96M	0	375K	1.81M	0	0	0
Other Income/Expense	15.75K	46.92K	-1.13M	-4.5M	188K	1.99M	783K	4.2M	1.96M	5.48M
Pretax Income+	-14.94M	-20.28M	-29.86M	-30.45M	-20.33M	-20.9M	-41.06M	-51.79M	-68.46M	-74.41M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	-19.82K	-11.37K	0	-29K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-14.94M	-20.28M	-29.86M	-30.42M	-20.33M	-20.9M	-41.06M	-51.79M	-68.46M	-74.41M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-0.31%	-0.36%	-0.47%	-0.02%	0.33%	-0.03%	-0.96%	-0.26%	-0.32%	-0.09%
Net Income (Continuing)	-14.94M	-20.28M	-29.86M	-30.45M	-20.33M	-20.9M	-41.06M	-51.79M	-68.46M	-74.41M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-30.14	-24.55	-26.83	-17.11	-3.54	-2.72	-2.32	-1.01	-1.33	-0.98
EPS Growth %	-0.11%	0.19%	-0.09%	0.36%	0.79%	0.23%	0.15%	0.56%	-0.32%	0.26%
EPS (Basic)	-30.14	-24.55	-26.83	-17.11	-3.54	-2.72	-2.26	-1.01	-1.33	-0.98
Diluted Shares Outstanding	495.46K	825.93K	1.11M	1.78M	5.75M	7.67M	19.49M	51.19M	51.47M	76M
Basic Shares Outstanding	495.46K	825.93K	1.11M	1.78M	5.75M	7.67M	18.2M	51.19M	51.47M	76M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Total Current Assets+	4.49M	4.93M	2.01M	12.14M	10.52M	41.99M	152.1M	104.91M	128.65M	171.15M
Cash & Short-Term Investments	4.06M	4.49M	1.65M	11.57M	9.96M	41.05M	150.41M	101.9M	126.87M	167.86M
Cash Only	4.06M	4.49M	1.65M	11.57M	9.96M	41.05M	150.41M	16.04M	70.4M	94.11M
Short-Term Investments	0	0	0	0	0	0	0	85.86M	56.48M	73.75M
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	430.09K	442.01K	361.92K	571K	0	0	0	0	1.78M	3.29M
Total Non-Current Assets+	6.41M	5.7M	495.1K	108K	447K	616K	316K	18.81M	4.08M	4.34M
Property, Plant & Equipment	5.98M	5.33M	368.37K	44K	416K	425K	168K	2.19M	1.98M	1.42M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	51.61K	44.32K	37.03K	29K	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	16.47M	263K	0
Other Non-Current Assets	375K	330.63K	89.69K	35K	31K	191K	148K	148K	1.84M	2.92M
Total Assets+	10.9M	10.63M	2.5M	12.25M	10.96M	42.61M	152.42M	123.72M	132.74M	175.49M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.03%	-0.03%	-0.76%	3.9%	-0.11%	2.89%	2.58%	-0.19%	0.07%	0.32%
Total Current Liabilities+	1.73M	1.77M	6.25M	8.38M	3.23M	1.97M	2.46M	5.2M	9.61M	11.91M
Accounts Payable	1.5M	926.04K	1.71M	563K	893K	1.03M	1.13M	3.27M	4.9M	5.81M
Days Payables Outstanding	66.26	26.89	584.34	4.28K	18.11K	29.06K	-	-	-	-
Short-Term Debt	83.13K	10K	3.44M	10K	0	0	0	0	0	0
Deferred Revenue (Current)	15.08K	108.06K	1000K	0	0	0	0	0	0	0
Other Current Liabilities	108.52K	131.08K	335.88K	6.53M	120K	77K	0	883K	1.81M	2.27M
Current Ratio	2.60x	2.78x	0.32x	1.45x	3.26x	21.34x	61.78x	20.18x	13.39x	14.37x
Quick Ratio	2.60x	2.78x	0.32x	1.45x	3.26x	21.34x	61.78x	20.18x	13.39x	14.37x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	400.04K	329.62K	215.62K	2.12M	374K	14.54M	487K	2.35M	2.13M	1.45M
Long-Term Debt	0	0	0	0	0	13.97M	0	0	0	0
Capital Lease Obligations	0	0	0	0	165K	187K	80K	1.94M	1.66M	983K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	329.62K	215.62K	2.12M	209K	387K	407K	412K	468K	468K
Total Liabilities	2.13M	2.1M	6.46M	10.5M	3.6M	16.51M	2.95M	7.55M	11.73M	13.36M
Total Debt+	83.13K	10K	3.43M	10K	410K	14.42M	188K	2.48M	2.23M	1.61M
Net Debt	-3.98M	-4.48M	1.79M	-11.56M	-9.54M	-26.63M	-150.22M	-13.56M	-68.17M	-92.49M
Debt / Equity	0.01x	0.00x	-	0.01x	0.06x	0.55x	0.00x	0.02x	0.02x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-2967.11x	-12742.35x	-41.69x	-5.23x	-	-61.05x	-23.16x	-	-	-
Total Equity+	8.77M	8.53M	-3.96M	1.75M	7.37M	26.1M	149.47M	116.17M	121M	162.13M
Equity Growth %	-0.03%	-0.03%	-1.46%	1.44%	3.2%	2.54%	4.73%	-0.22%	0.04%	0.34%
Book Value per Share	17.71	10.33	-3.56	0.99	1.28	3.40	7.67	2.27	2.35	2.13
Total Shareholders' Equity	8.77M	8.53M	-3.96M	1.75M	7.37M	26.1M	149.47M	116.17M	121M	162.13M
Common Stock	35.11K	49.23K	62.17K	210K	6K	8K	34K	37K	53K	87K
Retained Earnings	-44.04M	-64.32M	-94.18M	-126.9M	-147.24M	-168.14M	-209.2M	-260.99M	-329.44M	-403.86M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-879.25K	-1.99M	-517.79K	0	0	0	0	-351K	-79K	-7K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Cash from Operations+	-10.49M	-13.31M	-14.11M	-15.3M	-24.17M	-20.44M	-39.62M	-44.48M	-57.37M	-69.08M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.48%	-0.27%	-0.06%	-0.08%	-0.58%	0.15%	-0.94%	-0.12%	-0.29%	-0.2%
Net Income	-14.94M	-20.28M	-29.86M	-30.45M	-20.33M	-20.9M	-41.06M	-51.79M	-68.46M	-74.41M
Depreciation & Amortization	751.25K	1.11M	1.07M	49K	18K	13K	13K	30K	36K	31K
Stock-Based Compensation	3.76M	6.01M	5.1M	2.64M	3.32M	3.96M	3.69M	7.27M	7.36M	7.12M
Deferred Taxes	0	0	2.93M	-17K	102K	-1.78M	0	-1.36M	0	0
Other Non-Cash Items	53.15K	1.2K	5.63M	4.12M	222K	384K	-1.61M	352K	595K	-1.86M
Working Capital Changes	-119.2K	-155.36K	1.03M	8.36M	-7.49M	-2.12M	-642K	1.02M	3.1M	47K
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	26.37K	112.35K	824.45K	-548K	330K	142K	-11K	2.14M	1.08M	1.42M
Cash from Investing+	-1.45M	-195.38K	1.73M	231K	0	0	0	-101.46M	48.7M	-14.54M
Capital Expenditures	-2.09M	-407.93K	-5.82K	-47K	0	0	0	-153K	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	637.67K	212.55K	1.74M	278	0	0	0	-101.46M	0	0
Cash from Financing+	10.73M	13.93M	9.54M	25M	22.55M	51.53M	148.98M	11.57M	63.03M	107.33M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-890.36K	-683.19K	-299.27K	0	-1.5M	-4.47M	31.39M	-759K	14.01M	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-12.58M	-13.72M	-14.12M	-15.35M	-24.17M	-20.44M	-39.62M	-44.63M	-57.37M	-69.08M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-0.23%	-0.09%	-0.03%	-0.09%	-0.57%	0.15%	-0.94%	-0.13%	-0.29%	-0.2%
FCF per Share	-25.39	-16.61	-12.68	-8.64	-4.20	-2.66	-2.03	-0.87	-1.11	-0.91
FCF Conversion (FCF/Net Income)	0.70x	0.66x	0.47x	0.50x	1.19x	0.98x	0.96x	0.86x	0.84x	0.93x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-167.56%	-234.41%	-1307.66%	-1736.13%	-446.05%	-124.92%	-46.77%	-38.99%	-57.73%	-52.56%
Return on Invested Capital (ROIC)	-256.42%	-344.65%	-2293.34%	-	-	-	-	-82.45%	-67.95%	-97.85%
Debt / Equity	0.01x	0.00x	-	0.01x	0.06x	0.55x	0.00x	0.02x	0.02x	0.01x
Interest Coverage	-2967.11x	-12742.35x	-41.69x	-5.23x	-	-61.05x	-23.16x	-	-	-
FCF Conversion	0.70x	0.66x	0.47x	0.50x	1.19x	0.98x	0.96x	0.86x	0.84x	0.93x

Frequently Asked Questions

Growth & Financials

Rezolute, Inc. (RZLT) grew revenue by 0.0% over the past year. Growth has been modest.

Rezolute, Inc. (RZLT) reported a net loss of $77.2M for fiscal year 2025.

Dividend & Returns

Rezolute, Inc. (RZLT) has a return on equity (ROE) of -52.6%. Negative ROE indicates the company is unprofitable.

Rezolute, Inc. (RZLT) had negative free cash flow of $70.5M in fiscal year 2025, likely due to heavy capital investments.